Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDI-PIO: Pioglitazone for Imatinib Discontinuation in CML
NCT02852486Phase 2Completed
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jun 2016
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pioglitazone in chronic myeloid leukemia (CML), sponsored by Universidade Estadual de Campinas. Started Jun 2016; status: completed.
02
Drugs
pioglitazone
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02852486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852486.